Terms ending in 2032
Every in-force patent on Mesoblast, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,301,978 | Method of Treating Graft Versus Host Disease In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 10,550,369 | Enhanced MSC Preparation In force · Medium confidence | Mesoblast International SARL | In force | Medium confidence | |
| US 8,637,004 | Purified Mesenchymal Stem Cell Compositions and Methods of Purifying Mesenchymal Stem Cell Compositions In force · High confidence | Mesoblast International Sàrl | In force | High confidence | |
| US 10,206,951 | Methods of Treating Multiple Sclerosis Using STRO-1+ and Tnap+ Multipotential Cells In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 9,265,796 | Methods of Treating or Preventing Rheumatic Disease In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 9,974,812 | Methods of Treating or Preventing Rheumatic Disease In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 10,596,199 | Methods of Treating or Preventing Rheumatic Disease In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 9,642,878 | Methods for Increasing Osteoblastic Function In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 11,135,249 | Methods for Increasing Osteoblastic Function In force · High confidence | Mesoblast, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.